HC Wainwright Analysts Raise Earnings Estimates for NextCure

NextCure, Inc. (NASDAQ:NXTC) – Research analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of NextCure in a research report issued on Wednesday, July 15th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($1.93) per share for the quarter, up from their previous forecast of ($2.09). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for NextCure’s current full-year earnings is ($7.89) per share. HC Wainwright also issued estimates for NextCure’s Q3 2026 earnings at ($2.00) EPS, Q4 2026 earnings at ($2.07) EPS, FY2026 earnings at ($7.88) EPS, FY2027 earnings at ($3.33) EPS, FY2028 earnings at ($3.18) EPS and FY2029 earnings at ($2.17) EPS.

Several other research analysts have also recently issued reports on NXTC. Wall Street Zen cut NextCure from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, NextCure currently has a consensus rating of “Hold” and a consensus target price of $19.00.

NextCure Stock Down 2.9%

Shares of NASDAQ:NXTC opened at $5.99 on Friday. NextCure has a 52 week low of $1.55 and a 52 week high of $15.74. The company has a market capitalization of $21.64 million, a price-to-earnings ratio of -0.35 and a beta of 1.42. The firm has a 50 day moving average of $4.43 and a 200 day moving average of $9.30.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, beating the consensus estimate of ($2.10) by $0.23.

Institutional Trading of NextCure

A number of hedge funds and other institutional investors have recently made changes to their positions in NXTC. Renaissance Technologies LLC boosted its position in shares of NextCure by 80.0% in the 1st quarter. Renaissance Technologies LLC now owns 60,534 shares of the company’s stock valued at $647,000 after purchasing an additional 26,900 shares during the period. Ikarian Capital LLC acquired a new position in NextCure during the fourth quarter worth approximately $3,382,000. Squadron Capital Management LLC acquired a new position in NextCure during the fourth quarter worth approximately $3,363,000. Millennium Management LLC purchased a new stake in NextCure in the fourth quarter valued at approximately $185,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of NextCure in the fourth quarter valued at approximately $988,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.